Last reviewed · How we verify
DAPA
At a glance
| Generic name | DAPA |
|---|---|
| Also known as | Farxiga 10 mg |
| Sponsor | Astrazeneca Ab |
| Target | Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Chronic heart failure
- Chronic kidney disease
- Diabetes mellitus type 1
- Diabetes mellitus type 2
Common side effects
- Diarrhea
- Nausea/Vomiting
Serious adverse events
- Renal impairment
- Increased blood creatinine
- Decreased renal creatinine clearance
- Urinary tract infection
Key clinical trials
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) (PHASE4)
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease (PHASE2)
- Dapagliflozin for Cardio-renal Protection After ICU Discharge (PHASE3)
- Dapagliflozin for Long COVID Syndrome (PHASE3)
- Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation (EARLY_PHASE1)
- Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAPA CI brief — competitive landscape report
- DAPA updates RSS · CI watch RSS
- Astrazeneca Ab portfolio CI